Product

Prednisolone Wockhardt

1 form: scored tablet. In force in Georgia: 1 of 1 (human register).

Forms and doses1 of 1 in force in Georgia

Form	Dose	Frequency	Georgia
5 mg, Scored tablet	No label dose in the reference yet	-	Georgia Yes, human In force until 21 Feb 2029 Human (Ministry of Health, RAMA) In the register: პრედნიზოლონი ვოკჰარდტი 5 მგ, აბი № რ-040294 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration Prednisolone Wockhardt 5 mg, Scored tablet tablet, human medicine vetman assessment vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient. Dog Systemic oral prednisolone as symptomatic or adjunct anti-inflammatory/immunosuppressive treatment for a diagnosed corticosteroid-responsive disease with cause-directed care and monitoring 6.9/10 Situational / acceptable vetman assessment Prednisolone Wockhardt 5 mg, tablet, human medicine Assessed clinical scopeDog · Systemic oral prednisolone as symptomatic or adjunct anti-inflammatory/immunosuppressive treatment for a diagnosed corticosteroid-responsive disease with cause-directed care and monitoring · By mouth Care settingVeterinarian-directed home treatment with diagnosis-specific induction, scheduled reassessment, lowest-effective-dose taper and laboratory/clinical monitoring proportional to dose and duration vetman score 6.9/10 Situational / acceptable Evidence confidence: Medium Georgia: Yes, human · № რ-040294 · Verified on 16 Oct 2026 Off-label use A clinically powerful and well-established systemic glucocorticoid when a corticosteroid-responsive diagnosis justifies it. Use the lowest effective dose, treat the underlying cause, screen important comorbidity and interactions, monitor dose/duration-dependent toxicity and taper sustained treatment rather than stopping abruptly. Regulatory and scientific credibility7.0/10 This exact human 5 mg scored tablet has sourced current registrations in Georgia and GB, a current identifiable UK SmPC and no exact EU/EEA or US registration in the checked registers. Veterinary use is off-label, although authorised veterinary 5 mg prednisolone tablets directly support species, route and strength. Clinical efficacy8.0/10 Prednisolone is an established, orally absorbed intermediate-duration glucocorticoid with strong guideline and authorised-veterinary support across inflammatory and immune-mediated canine disease. It can be highly effective when the diagnosis and dose target are correct, but benefit is symptomatic or adjunctive and varies by underlying disease; steroid-sparing or local therapy may be preferable for chronic control. Safety and tolerability5.5/10 Short, appropriately selected courses are usually manageable, but dose- and duration-dependent polyuria/polydipsia, polyphagia, gastrointestinal signs, muscle/skin change, infection, thrombotic and metabolic effects are well documented. Chronic or high-dose use can cause iatrogenic hyperadrenocorticism and HPA suppression; abrupt withdrawal after sustained therapy risks adrenal insufficiency and relapse. Clinical practicality7.0/10 A stable 5 mg scored tablet is easy to store and administer and suits many small-to-medium canine anti-inflammatory doses, but the score line should be used for equal division only when the exact instruction confirms it. Large-dog or immunosuppressive regimens can require many tablets, and alternate-day taper schedules increase prescribing and adherence complexity. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags Do not use as a substitute for diagnosis or cause-directed treatment. Prednisolone can suppress fever, pain and inflammation while an infection, neoplasia, endocrine disorder or other underlying disease progresses. Do not start immunosuppressive prednisolone with an uncontrolled viral, fungal, bacterial or parasitic infection. Establish appropriate antimicrobial or antiparasitic control first or concurrently when steroid benefit is essential. Avoid concurrent NSAIDs and allow an indication-appropriate washout when switching; the combination materially increases gastrointestinal ulceration, perforation and bleeding risk. Avoid use with active gastrointestinal ulceration. Avoid or use only after explicit specialist benefit-risk assessment in diabetes mellitus, hyperadrenocorticism, uncontrolled hypertension, glaucoma, osteoporosis, important cardiac or renal dysfunction, corneal ulceration or major thrombotic risk. Do not give modified-live vaccines during immunosuppressive treatment. Review timing of vaccination and immune response before starting and after stopping systemic prednisolone. For courses beyond a brief induction, record weight, appetite, water intake/urination, skin and muscle condition, blood pressure and infection signs; monitor CBC, chemistry, glucose, urine and culture where dose, duration or patient risk warrants it. Use the lowest effective dose and reassess response early. After sustained supraphysiologic treatment, taper according to disease control and exposure; abrupt withdrawal can cause adrenal insufficiency, hypotension, weakness, gastrointestinal signs or relapse. Review all concurrent medicines. Enzyme inducers may reduce effect, strong metabolism inhibitors may increase exposure, diuretics can worsen potassium loss, insulin needs can change and other immunosuppressants increase infection risk. Safety of these exact human products in breeding, pregnant or lactating dogs and cats is not established. Glucocorticoids can affect fetal development, parturition, growth and immune response; use only after a documented veterinary benefit-risk assessment. Assessment sources Wockhardt prednisolone 5 mg SmPC2021 Prednicortone 5 mg veterinary SPC2025 Prednizol 5 mg UPD2026 MSD corticosteroids2026 MSD prednisolone dosing2026 MSD airway glucocorticoids2026 Feline oral prednisolone PK2013 Canine glucocorticoid AEs2020 Canine prednisolone HPA study2025 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Cat Systemic oral prednisolone as symptomatic or adjunct anti-inflammatory/immunosuppressive treatment for a diagnosed corticosteroid-responsive disease with cause-directed care and monitoring 7.2/10 Good vetman assessment Prednisolone Wockhardt 5 mg, tablet, human medicine Assessed clinical scopeCat · Systemic oral prednisolone as symptomatic or adjunct anti-inflammatory/immunosuppressive treatment for a diagnosed corticosteroid-responsive disease with cause-directed care and monitoring · By mouth Care settingVeterinarian-directed home treatment with diagnosis-specific induction, scheduled reassessment, lowest-effective-dose taper and laboratory/clinical monitoring proportional to dose and duration vetman score 7.2/10 Good Evidence confidence: Medium Georgia: Yes, human · № რ-040294 · Verified on 16 Oct 2026 Off-label use A clinically powerful and well-established systemic glucocorticoid when a corticosteroid-responsive diagnosis justifies it. Use the lowest effective dose, treat the underlying cause, screen important comorbidity and interactions, monitor dose/duration-dependent toxicity and taper sustained treatment rather than stopping abruptly. Regulatory and scientific credibility7.0/10 This exact human 5 mg scored tablet has sourced current registrations in Georgia and GB, a current identifiable UK SmPC and no exact EU/EEA or US registration in the checked registers. Veterinary use is off-label, although authorised veterinary 5 mg prednisolone tablets directly support species, route and strength. Clinical efficacy8.5/10 Prednisolone is an established first-line systemic glucocorticoid for many corticosteroid-responsive feline diseases and is pharmacologically preferable to prednisone when reliable hepatic activation is uncertain. Authorised veterinary 5 mg products and feline disposition data support the species and route, but response remains diagnosis-dependent and the drug does not replace treatment of infection or another underlying cause. Safety and tolerability6.0/10 Cats may show fewer classic chronic glucocorticoid signs than dogs, but infection, diabetes, skin fragility, heart failure risk, gastrointestinal ulceration and HPA suppression remain clinically important. High-dose immunosuppression and prolonged treatment require active monitoring and tapering; pregnancy, uncontrolled infection and important comorbidity materially narrow the safety margin. Clinical practicality7.5/10 A 5 mg tablet is close to many common feline anti-inflammatory dose units and is easier to store and administer than compounded liquid for many cats. Exact division must follow the product instruction; taste, pill acceptance, daily induction, monitoring and a multi-step taper can still be substantial treatment burdens. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags Do not use as a substitute for diagnosis or cause-directed treatment. Prednisolone can suppress fever, pain and inflammation while an infection, neoplasia, endocrine disorder or other underlying disease progresses. Do not start immunosuppressive prednisolone with an uncontrolled viral, fungal, bacterial or parasitic infection. Establish appropriate antimicrobial or antiparasitic control first or concurrently when steroid benefit is essential. Avoid concurrent NSAIDs and allow an indication-appropriate washout when switching; the combination materially increases gastrointestinal ulceration, perforation and bleeding risk. Avoid use with active gastrointestinal ulceration. Avoid or use only after explicit specialist benefit-risk assessment in diabetes mellitus, hyperadrenocorticism, uncontrolled hypertension, glaucoma, osteoporosis, important cardiac or renal dysfunction, corneal ulceration or major thrombotic risk. Do not give modified-live vaccines during immunosuppressive treatment. Review timing of vaccination and immune response before starting and after stopping systemic prednisolone. For courses beyond a brief induction, record weight, appetite, water intake/urination, skin and muscle condition, blood pressure and infection signs; monitor CBC, chemistry, glucose, urine and culture where dose, duration or patient risk warrants it. Use the lowest effective dose and reassess response early. After sustained supraphysiologic treatment, taper according to disease control and exposure; abrupt withdrawal can cause adrenal insufficiency, hypotension, weakness, gastrointestinal signs or relapse. Review all concurrent medicines. Enzyme inducers may reduce effect, strong metabolism inhibitors may increase exposure, diuretics can worsen potassium loss, insulin needs can change and other immunosuppressants increase infection risk. Safety of these exact human products in breeding, pregnant or lactating dogs and cats is not established. Glucocorticoids can affect fetal development, parturition, growth and immune response; use only after a documented veterinary benefit-risk assessment. Assessment sources Wockhardt prednisolone 5 mg SmPC2021 Prednicortone 5 mg veterinary SPC2025 Prednizol 5 mg UPD2026 MSD corticosteroids2026 MSD prednisolone dosing2026 MSD airway glucocorticoids2026 Feline oral prednisolone PK2013 Canine glucocorticoid AEs2020 Canine prednisolone HPA study2025 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Composition / strength Prednisolone5 mg Formulation Type Scored tablet Administration route By mouth Manufacturer Wockhardt Registration Georgia Yes, human In force until 21 Feb 2029 Human (Ministry of Health, RAMA) In the register: პრედნიზოლონი ვოკჰარდტი 5 მგ, აბი № რ-040294 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026 EU No EMA Article 57 database (all medicines authorised in the EU/EEA), 09.10.2026 Verified on: 16 Oct 2026 UK Yes, human № PL298310177, PL298310178 MHRA Products (UK) Verified on: 16 Oct 2026 US No Drugs@FDA (openFDA) Verified on: 16 Oct 2026 Controlled in Georgia No Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n. matsne.gov.ge Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Prednisolone

Dose calculatorCalculates the active-substance amount; it is not a prescription.

PatientSpecies and weight will be filled in automatically in other calculators.

Species Weight (kg)

Indication

Selected dose

Product presentation

Dose	Species	Indication	Route	Frequency	Source
0.1–2 mg/kg	Dog, Cat	Inflammation	By mouth	once daily	VMD SPC 2026 Official product label (SPC), VMD, UK Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there. Prednicare 5 mg Tablets - Summary of Product Characteristics UK Veterinary Medicines Directorate, Product Information Database, 2026 Open the source ↗
0.5–4 mg/kg	Dog, Cat	Immune-Mediated Disease	By mouth	once daily	VMD SPC 2025 Official product label (SPC), VMD, UK Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there. Prednicortone 5 mg Tablets for Dogs and Cats - Summary of Product Characteristics UK Veterinary Medicines Directorate, Product Information Database, 2025 Open the source ↗
0.5–1 mg/kg	Dog, Cat	Inflammation	Intramuscular	Single dose	VMD SPC 2023 Official product label (SPC), VMD, UK Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there. Cortico Veyxin 10 mg/ml Suspension for Injection - Summary of Product Characteristics UK Veterinary Medicines Directorate, Product Information Database, 2023 Open the source ↗

Known Contraindications

Critical
An uncontrolled viral, fungal, or parasitic infection is an absolute contraindication. The parasitic-infection restriction is specified on the Prednicare label.
Critical
Diabetes mellitus is an absolute contraindication on the Prednicare and Prednicortone labels.

Sources: Product label
Critical
Hyperadrenocorticism is an absolute contraindication on the Prednicare and Prednicortone labels.

Sources: Product label
Critical
Osteoporosis is an absolute contraindication on the Prednicare and Prednicortone labels.

Sources: Product label
Critical
Corneal ulceration is an absolute contraindication on the Prednicare and Prednicortone labels.

Sources: Product label
Critical
Glaucoma is an absolute contraindication on the Prednicare and Prednicortone labels.

Sources: Product label
Critical
Hypersensitivity to prednisolone or any excipient is an absolute contraindication on the Prednicare and Prednicortone labels.

Sources: Product label
Critical
Burn injury is listed as a contraindication on the Prednicortone label but not on the other two reviewed labels.

Sources: Product label
Critical
Cataract is listed as a contraindication on the Cortico Veyxin label.

Sources: Product label
Critical
Hypocalcaemia is listed as a contraindication on the Cortico Veyxin label.

Sources: Product label
Critical
Hypertension is listed as a contraindication on the Cortico Veyxin label.

Sources: Product label
Critical
Pancreatitis is listed as a contraindication on the Cortico Veyxin label.

Sources: Product label
Critical
A poorly healing wound or fracture is listed as a contraindication on the Cortico Veyxin label.

Sources: Product label
Critical
General immunodeficiency is listed as a contraindication on the Cortico Veyxin label.

Sources: Product label
Critical
Gastrointestinal ulceration is an absolute contraindication on all three reviewed labels. Concomitant corticosteroid and NSAID treatment further increases the risk of ulceration; see the interaction warnings.

Sources: Product label
Critical
cardiac or renal dysfunction

Sources: Product label
Critical
Severe renal impairment is an absolute contraindication on the Prednicare label.

Sources: Product label
Critical
Do not use during pregnancy. Some corticosteroid products specify this restriction for the final third of gestation.
Warning
Use in growing animals carries a risk of growth retardation, suppression of bone growth, and damage to the bone matrix.
Warning
Do not use with a live attenuated vaccine because corticosteroids suppress the immune response to vaccination. The Prednicortone label also prohibits use within 2 weeks after vaccination.
Warning
very rare

Known Drug Interactions

Contraindicated Meloxicam + Prednisolone
Concomitant use of corticosteroids and non-steroidal anti-inflammatory drugs can worsen gastrointestinal ulceration.

Recommendation: Do not administer together. Observe an appropriate washout period when switching and monitor for melena, vomiting, and reduced appetite.

Sources: Product label
Contraindicated Robenacoxib + Prednisolone
Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.

Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
Major warning Prednisolone + Insulin glargine
Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.

Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.

Sources: FDA · AAHA
Major warning Prednisolone + Insulin human
Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.

Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.

Sources: FDA · AAHA
Major warning Furosemide + Prednisolone
Concurrent use with drugs affecting electrolyte balance (corticosteroids, other diuretics, amphotericin B, cardiac glycosides) requires careful monitoring.

Recommendation: Monitor electrolytes, particularly potassium. Check periodically during prolonged combination therapy.

Sources: VMD SPC · VMD
Major warning Carprofen + Prednisolone
Do not give other non-steroidal anti-inflammatory drugs or glucocorticoids concurrently with carprofen or within 24 hours of treatment because gastrointestinal ulceration or perforation may occur.

Recommendation: Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.

Sources: FDA

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Prednisolone Wockhardt

Forms and doses1 of 1 in force in Georgia